Dr. David Martí Aguado
Emerging Investigator
Research Group on the Study of Cardiometabolic and Renal Risk
Presentation
Dr. David Martí Aguado is Hepatologist at the Digestive Disease Department of Clinic University Hospital of Valencia. His passion for medical research started when studying the Master’s Degrees in Clinical Medicine Research from University Miguel Hernández of Elche. After that, he received a Río Hortega award (2020-2022) allowing him to combine translational research activities with clinical tasks focused on the management of patients with metabolic dysfunction-associated steatotic liver disease (MASLD). Since then, he has been part of the Cardiometabolic and Renal Risk Study Group from Health Research Institute INCLIVA. He performed his Doctoral Thesis on “Imaging Biomarkers in Chronic Liver Diseases”, obtaining the mentions of (I) Extraordinary Award from the University of Valencia, (II) Award for the Best Thesis from the Official College of Physicians of Valencia in 2021, (III) Award for Doctorate in Clinical Medical Sciences from the Royal National Academy of Medicine in 2023. He obtained an international mobility grant from the University of Valencia to complete two predoctoral stays at the University of Pittsburgh (United States) and the National Center for Cardiovascular Research (Instituto de Salud Carlos III). He also performed a postdoctoral fellowship at University California San Diego (with the Liver Imaging Group at MASLD Research Center)
Since 2023, he has consolidated his position as a clinical researcher with a Joan Rodés award. He coordinates an international registry named “Virtual Liver Biopsy” that aims to generate and integrate multidimensional data to model computational tools based on Artificial Intelligence that define the biological processes involved in the phenotypic variability of MASLD, and to identify a signature of the disease that predicts its risk of progression. In the last years, this registry has made significant contributions in the management of MASLD patients with ground-breaking publications. He is Principal Investigator of several competitive projects and leads an Emerging Research Group supported of the Generalitat Valenciana (CIGE/2022/37). To be mentioned, he received the Healthcare Innovation Award from the Malvarrosa Clinical Health Department. He has supervised several Final Degree Projects at the Polytechnic University of Valencia and University of Valencia and is currently supervising 3 Doctoral Thesis. He is also a member of the Governing Board of the Spanish Association for the Study of the Liver (AEEH) and has participated as an expert in MASLD for the Executive Commission of the National Liver Health Plan: Challenge 2032.
Publications
MASLD biomarkers: are we facing a new era?. Maya-Miles D, Ampuero J, Marti-Aguado D, Conthe A, Gallego-Duran R. Gastroenterologia y Hepatologia. 2024 Feb 12:S0210-5705(24)00053-0. doi: 10.1016/j.gastrohep.2024.02.004. PMID: 38355096
Biological treatment interruption in Inflammatory Bowel Disease: motivation and predictive factors. González MRD, Ballester MP, Romero-González E, Sánchez-Pardo AM, Marti-Aguado D, Tosca J, Suria C, Ausejo RA, Moreno IP, Silvestre MDP, Pérez MM, Bosca-Watts MM. Gastroenterologia y Hepatologia. 2023 Nov;46(9):671-681. doi: 10.1016/j.gastrohep.2022.10.021. PMID: 36375696
Current dilemmas in Hepatitis Virus C management. What should we do after achieving sustained virologic response?. Conthe A, Ahumada A, Durán RG, Marti-Aguado D, Ibáñez-Samaniego L. Gastroenterologia y Hepatología. 2023 Oct 7:S0210-5705(23)00434-X. doi: 10.1016/j.gastrohep.2023.10.001. PMID: 37813183
Development and validation of an image biomarker to identify metabolic dysfunction associated steatohepatitis: MR-MASH score. Marti-Aguado D, Arnouk J, Liang J, Lara-Romero C, Behari J, Furlan A, Jimenez-Pastor A, Ten-Esteve A, Alfaro-Cervello C, Bauza M, Gallen-Peris A, Gimeno-Torres M, Merino-Murgui V, Perez-Girbes A, Benlloch S, Perez-Rojas J, Puglia V, Ferrández-Izquierdo A, Aguilera V, Giesteira B, França M, Monton C, Escudero-García D, Alberich-Bayarri A, Serra M, Bataller R, Romero-Gomez M, Marti-Bonmati L. Liver International. 2023 Oct 30. doi: 10.1111/liv.15766. PMID: 37904633
Pancreatic steatosis and iron overload increases cardiovascular risk in non-alcoholic fatty liver disease. Marti-Aguado D, Ten-Esteve A, Baracaldo-Silva C, Crespo A, Coello E, Merino-Murgui V, Fernandez-Paton M, Alfaro-Cervello C, Sanchez-Martin A, Bauza M, Jimenez-Pastor A, Perez-Girbes A, Benlloch S, Perez-Rojas J, Puglia V, Ferrandez A, Aguilera V, Latorre M, Monton C, Escudero-Garcia D, Bosch-Roig I, Alberich-Bayarri A, Marti-Bonmati L. Frontiers in Endocrinology. 2023 Aug 3;14:1213441. doi: 10.3389/fendo.2023.1213441. PMID: 37600695
Cigarette smoking and liver diseases. Marti-Aguado D, Clemente-Sanchez A, Bataller R. Journal of Hepatology. 2022 Jul;77(1):191-205. doi: 10.1016/j.jhep.2022.01.016. PMID: 35131406
Thiopurine adherence: high prevalence with low impact in UC outcomes. Gomez-Medina C, Capilla-Lozano M, Ballester Ferre M, Marti-Aguado D, Crespo A, Bosca-Watts M, Navarro Cortes P, Anton R, Pascual Moreno I, Tosca Cuquerella J, Minguez Perez M. Revista Española de Enfermedades Digestivas. 2022 Feb;114(2):76-82. doi: 10.17235/reed.2021.7630/2020. PMID: 33733802
Digital pathology: accurate technique for quantitative assessment of histological features in metabolic-associated fatty liver disease. Marti-Aguado D, Rodriguez-Ortega A, Mestre-Alagarda C, Bauza M, Valero-Perez E, Alfaro-Cervello C, Benlloch S, Perez-Rojas J, Ferrandez A, Alemany-Monraval P, Escudero-Garcia D, Monton C, Aguilera V, Alberich-Bayarri A, Serra M, Marti-Bonmati L. Alimentary Pharmacology & Therapeutics. 2021 Jan;53(1):160-171. doi: 10.1111/apt.16100. PMID: 32981113
Precise whole liver automatic segmentation and quantification of PDFF and R2* on MR images. Jimenez-Pastor A, Alberich-Bayarri A, Lopez-Gonzalez R, Marti-Aguado D, Frana M, Bachmann R, Mazzucco J, Marti-Bonmati L. European Radiology. 2021 Oct;31(10):7876-7887. doi: 10.1007/s00330-021-07838-5. PMID: 33768292
Risk factors and management strategies associated with non-response to aminosalicylates for maintenance treatment in ulcerative colitis. Marti-Aguado D, Ballester M, Minguez M. Revista Espanola de Enfermedades Digestivas. 2021 Jun;113(6):447-453. doi: 10.17235/reed.2021.7797/2021. PMID: 33569968
Transjugular intrahepatic portosystemic shunt reduces hospital care burden in patients with decompensated cirrosis. Ballester M, Lluch P, Gomez C, Capilla M, Tosca J, Marti-Aguado D, Guijarro J, Minguez M. Internal and Emergency Medicine. 2021 Sep;16(6):1519-1527. doi: 10.1007/s11739-020-02602-x. PMID: 33400160
+ Info
Doctoral candidate: Martí Aguado, David
Director(s): Martí Bonmatí, Luis; Serra Desfilis, Miguel Ángel
Date of the defense: 29/06/2021
University: Universitat de València